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Introduction:  Neuromuscular  blockade  (NMB)  is  widely  used  during  therapeutic  hypothermia  (TH) after
cardiac arrest  but  its  effect  on  patient  outcomes  is unclear.  We  compared  the  effects  of NMB  on  neu-
rological  outcomes  and  frequency  of  early-onset  pneumonia  in cardiac-arrest  survivors  managed  with
TH.
Methods: We  retrospectively  studied  consecutive  adult  cardiac-arrest  survivors  managed  with  TH  in a
tertiary-level  intensive  care  unit  between  January  2008  and  July 2013.  Patients  given continuous  NMB
for persistent  shivering  were  compared  to those  managed  without  NMB.  Cases  of early-onset  pneumonia
and  vital  status  at  ICU  discharge  were  recorded.  To  avoid  bias  due  to  between-group  baseline  differences,
we  adjusted  the  analysis  on a  propensity  score.
Results: Of 311  cardiac-arrest  survivors,  144  received  TH, including  117  with continuous  NMB  and  27
without  NMBs.  ICU mortality  was  lower  with  NMB  (hazard  ratio  [HR],  0.54  [0.32;  0.89],  p  = 0.016)  but  the
difference  was  not  signiﬁcant  after  adjustment  on the  propensity  score  (HR,  0.70  [0.39; 1.25],  p  =  0.22).
The  proportion  of patients  with  good  neurological  outcomes  was  not  signiﬁcantly  different  (36% with
and  22%  without  NMB,  p = 0.16).  Early-onset  pneumonia  was  more  common  with  NMB  (HR,  2.36  [1.24;
4.50],  p  =  0.009)  but  the  difference  was  not  signiﬁcant  after  adjustment  on the propensity  score  (HR,  1.68
[0.90;  3.16],  p =  0.10).
Conclusions:  Continuous  intravenous  NMB  during  TH  after  cardiac  arrest  has  potential  owns  effects  on
ICU  survival  with  a  trend  increase  in  the  frequency  of  early-onset  pneumonia.  Randomised  controlled
trials  are  needed  to  deﬁne  the  role for NMB  among  treatments  for TH-induced  shivering.
rs.  Pu©  2014  The  Autho
. IntroductionCardiac arrest occurs in 250,000–300,000 individuals each year
n Europe.1 Only 5–35% of these patients leave the hospital alive
Abbreviations: ICU, intensive care unit; NMB, neuromuscular blocker/blockade;
OSC, return of spontaneous circulation; SD, standard deviation; TH, therapeutic
ypothermia; TOF, train of four.
 A  Spanish translated version of the abstract of this article appears as Appendix
n  the ﬁnal online version at http://dx.doi.org/10.1016/j.resuscitation.2014.05.017.
∗ Corresponding author at: Service de Reanimation, Centre Hospitalier Départe-
ental de la Vendée, 85000 La Roche-sur-Yon, France.
E-mail address: jean-baptiste.lascarrou@chd-vendee.fr (J.B. Lascarrou).
ttp://dx.doi.org/10.1016/j.resuscitation.2014.05.017
300-9572/© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open acce
y-nc-nd/3.0/).blished  by Elsevier  Ireland  Ltd.  This  is an open  access  article  under  the CC
BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
with minimal to moderate neurological impairments.2 Two stud-
ies established the beneﬁcial effect in cardiac-arrest survivors of
therapeutic hypothermia (TH) with a target core temperature of
32–34 ◦C.3,4 TH is now the standard of care for cardiac-arrest
survivors, according to recommendations issued by the Interna-
tional Liaison Committee fOr Resuscitation (ILCOR) and European
Resuscitation Council (ERC) 5 and is widely used in Europe and
throughout the world.6,7
The optimal modalities of TH, however, remain unclear. Thus,
uncertainty exists about the optimal time of hypothermia induc-
tion, rate of cooling, duration of hypothermia, target temperature,
and rate of rewarming. During the induction and warming phases, a
physiological reaction mediated by the hypothalamus may  result in
ss article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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hivering.8 Shivering increases metabolic needs and body temper-
ture, thus counteracting the beneﬁcial effects of TH. Many drugs
nd physical factors can be used to decrease shivering. Sedatives
nd neuromuscular blockers (NMBs) were used routinely in the two
tudies that established the beneﬁts of TH.3,4 Routine NMB admin-
stration not only decreases shivering, but also facilitates both the
apid achievement and the maintenance of the target temperature.
owever, recently developed active cooling techniques can be used
o reach the target temperature without administering NMBs.9,10
inally, in combination with these techniques, the administration
f ﬂuids at 4 ◦C facilitates TH induction.11–13
NMB  therapy has limitations in cardiac-arrest survivors. NMBs
o not suppress the central hypothalamic activation by cold that
s responsible for shivering but merely eliminate the peripheral
esponse.8 NMB  therapy is associated with an increased risk of
neumonia 14 and with critical-illness neuromyopathy and its
ttendant morbidity.15 NMB  therapy precludes sedation-depth
onitoring and may  therefore unnecessarily delay the neurolog-
cal evaluation when sedation is too deep or increase the risk of
osttraumatic stress disorder when sedation is too superﬁcial.16
In our intensive care unit (ICU), since 2008, we  have not used
MBs routinely in patients receiving TH. The aim of this study was
o compare neurological outcomes and the frequency of early-onset
neumonia in cardiac-arrest survivors managed with TH and either
ontinuous intravenous NMB  therapy for shivering or no NMB  ther-
py.
. Materials and methods
We  conducted an observational retrospective study of cardiac-
rrest survivors managed using TH. According to French legislation
articles L.1121-1 paragraph 1 and R1121-2, Public Health Code),
either informed consent nor ethics committee approval was
equired.
.1. Study population
The study was performed in the medical/surgical ICU of the
egional hospital centre in La Roche-Sur-Yon, France, which serves
 population of over 600,000. We  included consecutive patients
dmitted to the ICU between January 2008 and July 2013 who
et the following criteria: age 18 years or older; out-of-hospital
ardiac arrest or in-hospital cardiac arrest followed by sustained
ecovery of spontaneous circulation (ROSC) deﬁned as the presence
f palpable pulses for >20 min; coma deﬁned as a Glasgow Coma
cale (GCS) score ≤8 at ICU admission; and presence of criteria for
sing TH as deﬁned in the written protocol of our ICU. We  included
oth patients with shockable rhythms (ventricular ﬁbrillation and
entricular tachycardia) and patients with non-shockable rhythms
electromechanical dissociation and asystole) according to Utstein
tyle criteria.17 Exclusion criteria were recovery of consciousness
efore ICU admission, pregnancy, clinical diagnosis of brain death at
CU admission, and treatment-limitation decision at ICU admission
ased on factors indicating a poor prognosis.
.2. Management of cardiac-arrest survivors
.2.1. Therapeutic hypothermia (TH)
TH was induced in all patients with shockable rhythms and
n those patients with non-shockable rhythms whose ROSC time
as shorter than 30 min.18 TH was induced by infusion of iso-onic saline at 4 ◦C. Core body temperature was  maintained at
3 ◦C for 24 h using either an external active method (cold tun-
el or blanket, Artic Sun BARD Medical, Louisville, CO, USA) or an
nternal active method (CoolGard catheter, Alsius/Zoll, Voisin leon 85 (2014) 1257–1262
Bretonneux, France) depending on availability of each. Controlled
warming from 33 ◦C to 37 ◦C was then performed with a target
temperature-increase rate of 0.3–0.5 ◦C per hour. Inadequate cool-
ing was deﬁned as a core temperature above 34 ◦C and overshoot
cooling as a core body temperature less than 32 ◦C during the main-
tenance phase.
2.2.2. Shivering and neuromuscular blockade
All patients were sedated with midazolam (Panpharma, Luitré,
France) and fentanyl (Renaudin, Itxassou, France). Doses were
adjusted to obtain a Richmond Agitation Sedation Scale score of
−5.19 Persistent shivering was treated according to a four-step pro-
tocol established in our ICU.
- Step 1, single intravenous bolus of a hypnotic agent and an
opioid20 in a dose that depended on the infusion rates of hyp-
notic and opioid drugs (i.e., midazolam 5-mg intravenous bolus if
the continuous midazolam infusion rate was  5 mg/h);
- Step 2, 2-fold increases in the infusion rates of the hypnotic agent
and opioid;
- Step 3, intravenous bolus of 10 mg  of the NMB  cisatracurium
(Nimbex®, GlaxoSmithKline, Marly-Le-Roy, France);
- and Step 4, continuous cisatracurium infusion in an initial dose
of 10 mg/h, allowing train-of-four monitoring (Innervator NS252,
Fisher & Paykel, Auckland, Australia) with a target of ≤1 twitch;
during re-warming, the infusion was  stopped when core body
temperature increased above 35 ◦C.
2.3. Data collection
All data were abstracted from the computerised patient ﬁles
(CareVue Chart, Philips, France). The following were collected:
age; gender; GCS score at admission, Simpliﬁed Acute Physiol-
ogy Score II (SAPS II) after 24 h; history of hypertension, diabetes,
and smoking; characteristics of the cardiac arrest (cardiac or non-
cardiac cause, no-ﬂow and low-ﬂow durations, and whether ST
was elevated immediately after the cardiac arrest); whether coro-
nary angiography was performed; whether coronary angioplasty
was performed successfully; occurrence of early-onset pneumonia
(<48 h); ICU stay duration; mechanical ventilation duration; and
vital status at ICU discharge.
2.3.1. Outcome measures
The neurological outcome was assessed based on the Cerebral
Performance Categories (CPC) score after 3 months, which was
determined by calling each patient’s usual physician. The CPC is
a validated scale that classiﬁes outcomes into ﬁve categories and is
widely used in studies of cardiac-arrest patients.21 Lower scores
indicate better performance and scores of 3 or higher indicate
severe disability or death. For our study, we  dichotomised the CPC
scores into two groups, good neurologic function (CPC 1 and 2) and
poor neurologic function (CPC 3-5), as done in earlier studies.3 Data
were entered into a study database and checked for completeness
and accuracy.
Pneumonia was  suspected in patients with compatible pul-
monary auscultation signs, leukopenia <4000/mm3 or leucocytosis
>10 000/mm3, and a new chest radiograph inﬁltrate. The diagnosis
was conﬁrmed by a quantitative bacteriological culture of a pro-
tected distal respiratory specimen (>103 cfu/mL); when no such
specimen was collected, diagnostic conﬁrmation relied on
purulence of the tracheal aspirates with hypoxaemia
(PaO2/FiO2 < 300) not explained by pulmonary oedema, pul-
monary embolism, or atelectasis. Body temperature was  not
taken into account for suspecting early onset pneumonia, as
the patients were receiving TH. Isolated microorganisms were
routinely subjected to antibiotic susceptibility testing. Pneumonia
scitation 85 (2014) 1257–1262 1259
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iagnosed within 48 h after intubation was deﬁned as early-onset
neumonia.22 Pneumonia diagnosed after 48 h of mechanical
entilation was deﬁned as ventilator-associated pneumonia (VAP).
.4. Statistical analysis
Descriptive statistics were computed for all baseline features
f the overall population and of the groups with and without
ontinuous NMB  therapy (NMB+ and NMB−, respectively). Fre-
uency and percentages were determined for categorical data
nd mean ± standard deviation (SD) or median and interquartile
ange for continuous data. Comparisons of the groups managed
ith and without NMBs (NMB+ and NMB− groups) relied on the
wo-tailed t-test or non-parametric Wilcoxon test for continuous
ata and on the chi-square test or Fisher exact test for categor-
cal data. Because 28-day ventilator-free days, 28-day ICU-free
ays, mechanical ventilation (MV) duration, and ICU length of stay
ere not normally distributed, they were analysed using the non-
arametric Wilcoxon test. Blood lactate level changes over time
ere compared between groups using a linear mixed model after
ogarithmic transformation. Crude proportions of patients with
arly-onset pneumonia and with a good neurological outcome (CPC
-2 after 3 months) were compared using chi-square tests. Because
eath competed with early-onset pneumonia, a sensitivity analy-
is was performed using competing-risk analysis. Survival to ICU
ischarge rates were estimated using the Kaplan–Meier method
nd compared using the log rank test. Multivariate analyses were
erformed with adjustment on a propensity score to eliminate
otential bias due to baseline differences between groups. The
ropensity score was estimated using a logistic regression model in
hich NMB  exposure was the dependent variable and age, shock-
ble rhythm, PO2/FiO2 ratio, no-ﬂow time, low-ﬂow time, and
itnessed cardiac arrest were covariates. Values of p less than 0.05
ere considered signiﬁcant unless stated otherwise. Imputation
f missing data was not performed. Statistical analyses were per-
ormed using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA) and
 3.0.2 (http://www.r-project.org).
. Results
.1. Study patients and comparison of the two groups
Fig. 1 is the patient ﬂowchart. Of 311 cardiac-arrest patients
dmitted during the study period, 167 were not included, for the
ollowing reasons: no TH (n = 136), brain death at ICU admission
n = 15), and no ROSC (n = 16). This left 144 patients for the study,
ncluding 117 (81%) given NMB  therapy during TH and 27 (19%)
anaged without NMB  therapy. Table 1 lists the main patient
haracteristics in the two groups. The only statistically signiﬁcant
aseline difference between the two groups was  for age, which
as older in the NMB− group (p = 0.014). Witnesses cardiac arrest,
hockable rhythm, no-ﬂow time, and low-ﬂow time were not sig-
iﬁcantly different between the two groups. Coronary angiography
as performed in 74 (63%) NMB+ patients and 13 (48%) NMB−
atients. Core temperatures were similar at ICU admission and
2 h later (p = 0.23). Also similar were the cooling methods used
p = 0.90) and time needed to reach the target temperature (p = 0.85)
Table 2).
.2. Early-onset pneumonia, 3-month neurological status, and
urvival (Table 3)The crude proportion of patients with early-onset pneumonia
as signiﬁcantly higher in the NMB+ group than in the NMB− group
64% vs. 33%; p = 0.005) even after handling death as a competing
vent (HR 2.36 [1.24; 4.50], p = 0.009) (Table 3). The difference wasFig. 1. Flowchart.
not signiﬁcant after adjustment on the propensity score (n = 120, HR
1.68 [0.9; 3.16], p = 0.10]. Of 84 patients with early-onset pneumo-
nia, 54 had bacteria recovered from respiratory specimens (Table 4).
Continuous NMB  infusion was  associated with a non-signiﬁcant
increase in MV  duration (4.0 days [2.3; 6.9] in the NMB+ group vs.
3.6 days [2.0; 4.5] in the NMB− group; p = 0.057) and a signiﬁcant
increase in ICU stay length (5.1 days [2.9; 9.7] in the NMB+ group vs.
4.0 days [2.2; 5.8] in the NMB− group); p = 0.049). Ventilator-free
days and ICU-free days by day 28 did not differ between the two
groups (Table 3).
Variations in serum lactate levels did not differ between the
groups. ICU mortality was lower in the NMB+ group compared to
the NMB− group (HR = 0.54 [0.32; 0.89], p = 0.016). However, the
between-group difference for ICU survival was  not signiﬁcant after
adjustment on the propensity score (n = 120, HR  = 0.70 [0.39; 1.25],
p = 0.22) (Table 3 and Fig. 2). The proportion of patients with a good
neurological outcome after 3 months was  not signiﬁcantly different
between the NMB+ and NMB− groups (Table 3).
4. Discussion
Most patients in our study required continuous NMB  ther-
apy for suppression of shivering during TH despite the use of a
stepwise protocol, in keeping with a previous descriptive study.6
The Kaplan–Meier analysis, but not the propensity-score analy-
sis, showed a signiﬁcant increase in ICU survival in patients given
NMB  compared to those managed without NMB. The proportion of
patients alive after 3 months with a CPC of 1 or 2 was not signiﬁ-
cantly different between these two groups. After adjustment on the
propensity score, NMB  therapy was associated with non-signiﬁcant
increases in early-onset pneumonia and ICU stay length.
NMB  therapy was used routinely in the two  studies that
established the efﬁcacy of TH in cardiac-arrest survivors:
1260 J.B. Lascarrou et al. / Resuscitation 85 (2014) 1257–1262
Table 1
Baseline characteristics of the groups managed with and without continuous intravenous neuromuscular blocker therapy.
NMB+ (n = 117) NMB− (n = 27) p value
Age in years, mean ± SD 58.5 ± 14.6 66.2 ± 12.7 0.014*
Males, n (%) 94 (80%) 19 (70%) 0.30
Witnessed cardiac arrest, n (%) 101 (86%) 25 (59%) 0.53
Location at cardiac arrest, n (%) 0.35
Home  37 (32%) 11 (41%)
Public place 59 (50%) 14 (52%)
In  the hospital 21 (18%) 2 (7%)
Hypertension, n (%) 67 (57%) 15 (55%) 1.00
Diabetes, n (%) 15 (13%) 6 (22%) 0.23
Smoker, n (%) 43 (37%) 5 (18%) 0.08
Shockable rhythm, n (%) 76 (65%) 12 (44%) 0.08
Cardiac cause, n (%) 88 (75%) 17 (63%) 0.23
ST  segment elevation, n (%) 39 (33%) 8 (30%) 0.82
No-ﬂow duration in min, mean ± SD 3.9 ± 5.2 2.4 ± 3.2 0.08
Low-ﬂow duration in min, mean ± SD 23.5 ± 19.9 27.0 ± 14.3 0.42
SAPS  II at ICU admission, mean ± SD 67.3 ± 16.4 73.2 ± 13.8 0.09
GCS  score at ICU admission, mean ± SD 3.5 ± 0.9 3.7 ± 1.4 0.47
Post-resuscitation shock, n (%) 78 (66%) 20 (74%) 0.50
STEMI, n (%) 39 (33%) 8 (30%) 0.82
Coronary angiogram, n (%) 74 (63%) 13 (48%) 0.19
Successful angioplasty, n (%) 40 (34%) 9 (33%) 1.00
PaO2/FiO2 ratio, median [Q1; Q3] 238.0 [153.0; 340.0] 233.0 [137.0; 340.0] 0.87
NMB, neuromuscular blocker therapy by continuous intravenous infusion during therapeutic hypothermia; SAPS II, Simpliﬁed Acute Physiology Score version II; ICU, intensive
care  unit; GCS, Glasgow Coma Scale; STEMI, ST-elevation myocardial infarction.
Table 2
Characteristics of therapeutic hypothermia in the groups managed with and without continuous intravenous neuromuscular blocker therapy.
NMB+ (n = 117) NMB− (n = 27) p value
Core temperature at H0, mean ± SD 35.4 ± 1.5 35.0 ± 1.2 0.20
Core  temperature at H12, mean ± SD 33.5 ± 0.9 33.8 ± 1.2 0.23
Cooling method, n (%)
Internal active method (CoolGardTM) 88 (76%) 20 (74%) 0.90
External active method (Cold tunnel or Artic SunTM) 29 (24%) 7 (26%)
Time  from ICU admission to target temperature, in min 365.1 (±334.1) 351.4 (±384.9) 0.85
Overshoot cooling,a n (%) 16 (14%) 3 (11%) 1.00
Inadequate cooling,b n (%) 40 (34%) 13 (48%) 0.19
Lactate at H0, median [Q1; Q3] 2.9 [1.9; 5.0] 4.0 [2.2; 6.2] 0.22
Lactate at H12, median [Q1; Q3] 1.9 [1.4; 4.1] 3.2 [1.5; 4.2] 0.32
Lactate at H24, median [Q1; Q3] 1.5 [1.1; 2.4] 1.4 [1.0; 2.7] 0.86
H
p
a
a
c
s
i
g
i
T
O
N
a0, time of ICU admission.
a Core temperature lower than 32 ◦C.
b Core temperature higher than 34 ◦C.
ancuronium was injected every 2 h in one study3 and vecuronium
s needed to suppress shivering in the other.4 Several experimental
nd clinical arguments support routine NMB  therapy during the
ooling phase of TH.23 In patients with acute respiratory distress
yndrome requiring mechanical ventilation, muscle relaxants
mproved oxygenation.24 In cardiac-arrest survivors, better oxy-
enation would be expected to lower the risk of secondary brain
njury due to systemic factors and to avoid regional hyperoxia,
able 3
utcomes in the groups managed with and without continuous intravenous neuromuscu
NMB+ (n = 11
Early-onset pneumonia, n (%) 75 (64%) 
Ventilator-associated pneumonia, n (%) 6 (5.1%) 
Nosocomial urinary tract infection, n (%) 4 (3.4%) 
Nosocomial bacteraemia, n (%) 11 (9.4%) 
MV  duration in days, median [Q1; Q3] 4.0 [2.3; 6.9] 
ICU  stay length in days, median [Q1; Q3] 5.1 [2.9; 9.7] 
Ventilator-free days by D28, median [Q1; Q3] 0.0 [0.0; 22.1]
ICU-free days by D28, median [Q1; Q3] 0.0 [0.0; 17.8]
Good  neurological outcomea, n (%) 42 (36%) 
MB, neuromuscular blocker; MV,  mechanical ventilation; ICU, intensive care unit; D28, 
a Cerebral Performance Category 1 or 2, 3 months after cardiac arrest.
b The sample size was too small for statistical testing.
§ Pneumonia diagnosed within 48 h after intubation was  deﬁned as early-onset pneum
ssociated pneumonia.particularly affecting the brain, which may  have deleterious effects
after cardiac arrest.25 In addition, the haemodynamic tolerance
of NMBs is good26,27 compared with analgesics or sedatives,
which are the alternatives for combatting shivering,23 although no
28well-designed comparative trials are available.
However, a recent literature review does not support routine
NMB  therapy during TH,23 and American Heart Association guide-
lines specify that the “Duration of NMB  agents should be kept to
lar blocker therapy.
7) NMB− (n = 27) p value
9 (33%) 0.005*
2 (7.4%) –b
0 (0%) –b
1 (3.7%) –b
3.6 [2.0; 4.5] 0.057
4.0 [2.2; 5.8] 0.049*
 0.0 [0.0; 23.0] 0.37
 0.0 [0.0; 18.8] 0.39
6 (22%) 0.26
day 28 after ICU admission.
onia and pneumonia diagnosed after 48 h of mechanical ventilation as ventilator-
J.B. Lascarrou et al. / Resuscitati
Fig. 2. ICU survival curve.
Table 4
Bacteria recovered in 54 of 84 patients with early-onset pneumonia.
Bacteria recovered n = 54
Gram-positive cocci
Staphylococcus aureus 16
Streptococcus pneumoniae 6
Other (Corynebacterium, group B streptococci) 4
Gram-negative bacteria
Haemophilus inﬂuenzae 15
Escherichia coli (ESBL, n = 2) 6
Enterobacter aerogenes 3
Klebsiella pneumoniae 3
Hafnia alvei 3
Proteus vulgaris 2
Aerococcus viridans 1
Serratia marcescens 1
Aeromonas sobria 1
Pseudomonas aeruginosa 1
Citrobacter freundii 1
Citrobacter koseri 1
E
a
e
i
i
o
h
i
d
a
e
a
t
d
t
a
s
w
7
i
bMore than one species 7
SBL, extended-spectrum beta-lactase production.
 minimum or avoided altogether”.5 NMBs have several unwanted
ffects in cardiac-arrest patients. First, they preclude clinical mon-
toring for seizures or status epilepticus, in which early treatment
mproves the likelihood of survival with good function.29 Sec-
nd, NMBs do not inhibit the central controller linked to central
ypothalamus receptors. Thus, they suppress shivering only by
nhibiting the motor response and consequently only partially
ecrease the metabolic demand of the brain.30 Third, NMB  ther-
py can mask inadequate sedation, which may  cancel out the
xpected beneﬁts from TH Finally, NMBs increase the risk of ICU-
cquired neuromyopathy, although to a small degree compared
o corticosteroids,31 particularly when used for short periods as
uring TH.24
Our results are in accordance with the only previous report
hat routine NMB  therapy was beneﬁcial during TH in cardiac-
rrest survivors. A post hoc analysis of data from an observational
tudy found that routine NMB  administration for 24 h after ROSC
as associated with a signiﬁcant increase in survival (odds ratio,
.23; 95% conﬁdence interval, 1.56–33.38) and with a signiﬁcant
mprovement in lactate clearance.32 The absence of signiﬁcant
eneﬁcial effects of NMB  therapy on ICU survival and 3-monthon 85 (2014) 1257–1262 1261
neurological outcome in our study may  be ascribable to inade-
quate statistical power, particularly for the analysis adjusted on
the propensity score. Shivering may  be linked chieﬂy to the devel-
opment of infectious complications (pneumonia in most cases)
rather than to a physiological cerebral response. Alternatively,
shivering may  indicate relative preservation of brain function:
thus, an observational study found better neurological outcomes in
patients with than without shivering during TH for cardiac arrest.33
In our study, early-onset pneumonia was  not signiﬁcantly more
common in the group given NMB  therapy. NMBs may  decrease
the clearance of respiratory secretions or increase the duration
of mechanical ventilation by inducing muscle weakness.34 We
used cisatracurium, whose anti-inﬂammatory effects 35 may  impair
immune responses within the lung, thereby increasing the risk of
bacterial pneumonia.34,36,37 Finally, variations in the use of NMBs
may  explain the conﬂicting results about the risk of infection asso-
ciated with TH.22,38
Our study has several limitations. The patients were identiﬁed
retrospectively and the number of patients managed without NMB
was small, albeit consistent with earlier reports.32,33 Continuous
NMB  infusion was only used when persistent shivering occurred,
according to a protocol that was  easy to apply, even by nurses and
residents. The deﬁnition of persistent shivering was not standard-
ised, and the Bedside Shivering Assessment Scale was not used,39
although TOF monitoring was  performed to assess neuromuscu-
lar blockade depth. However, the reliability of TOF monitoring
in patients with hypothermia,23 and more generally in the ICU,
has been challenged.40 Hypothermia may  potentiate the effect of
NMBs.41 We  had no speciﬁc protocol for managing bacterial pneu-
monia after cardiac arrest. However, no changes in the ICU team
occurred during the study period. The frequency of early-onset
pneumonia in our study is consistent with earlier data.22 Because of
the observational design of our study, the better prognosis of NMB+
group may  be ascribable to selection bias. However, all patients
received TH (i.e., none had early treatment-limitation decisions)
and acute illness severity as assessed by the SAPS II was  not sig-
niﬁcantly different between the two groups. Last, our study lacked
sufﬁcient power to draw deﬁnitive conclusions about patient out-
comes. Nevertheless, our study is the ﬁrst to report the effects of
NMB treatment for shivering according to a pre-established proto-
col during TH for cardiac arrest. The data were carefully collected
and analysed, thus providing reliable results.
5. Conclusion
NMB  therapy to suppress shivering was given to most patients
despite the use of a step-wise protocol speciﬁcally designed to
limit NMB  use. Our results suggest a beneﬁcial effect of continu-
ous intravenous NMB  therapy on survival of patients treated with
TH after cardiac arrest. However, NMB  therapy was also associ-
ated with a non-signiﬁcant increase in the frequency of early-onset
pneumonia. Adequately powered randomised controlled trials are
warranted to assess the risk/beneﬁt ratio of NMB  therapy during
TH after cardiac arrest, especially in the new era of targeted tem-
perature management.
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